CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
This compares to the stock's 7% loss over the past four weeks. This rise in share price is attributable to positive investor expectations for the company's sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is the first FDA-approved gene therapy based on CRISPR technology. It is approved to treat two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). We expect management to start recording revenues from Casgevy sales in the second half of 2024. This company is expected to post quarterly loss of $1.37 per share in its upcoming report, which represents a year-over-year change of -39.8%. Revenues are expected to be $8.39 million, down 88% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between tren
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- This Healthcare Growth Stock Could Be a Steal of a Deal Right Now [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Royal Bank of Canada from $60.00 to $53.00. They now have a "sector perform" rating on the stock.MarketBeat
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 10/15/24 - Form 4
- 10/15/24 - Form 4
- 8/12/24 - Form 4
- CRSP's page on the SEC website